An upcoming study could show whether diabetes drugs like Novo’s Victoza might have an effect on slowing cognitive decline.
The first-line Checkmate-9ER study will read out soon, and could show whether two arch rivals can together defeat a common enemy.
By the end of December poziotinib will deliver results that could justify the strategic refocusing Spectrum undertook this year.
Two phase III studies could determine whether the Canadian biotech has an approvable product, but the setting will initially be narrow.
Amarin’s Vascepa is widely expected to receive approval in a huge new patient population. So why has the company not been bought?
The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…
Iterum should soon find out if it has an approvable asset in the antibiotic sulopenem, but even if the group succeeds it still has a hard road ahead.
Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
Genfit's quiet delay means it will be five years since a Nash failure before investors find out whether pressing on into phase III was worth it.